Elicio Therapeutics Inc
Elicio Therapeutics Inc (ELTX) Covered Calls
Elicio Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 63.49%, average versus the past year. ELTX's highest covered call setup is the $5.00 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 233.33% out of the money with 98 days to expiration, a 236.67% return until expiration, and a 881.46% theoretical annualized return. Across the setups shown, annualized returns run from 148.06% to 881.46% at strikes between $2.50 and $5.00, with 98 to 189 days to expiration, as of Nov 13, 2026.
Read more
Running ELTX covered calls helps you generate income from Elicio Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ELTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ELTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ELTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ELTX covered call is worth writing.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
| 2027-02-19 | 98 | 5.00 | 233.33 | 0.05 | 0.40 | 355.00 | 236.67 | 881.46 | -3.33 | +0.33 | 355 | 0.35 |
| 2027-05-21 | 189 | 2.50 | 66.67 | 0.15 | 0.65 | 115.00 | 76.67 | 148.06 | -10.00 | +0.53 | 565 | 0.50 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank63.49% Moderate
- Market cap (M$)42
- 52 weeks high-90.75%
- 52 weeks low18.40%
- Analyst recommendationStrong Buy
1.40 - Target price$14.12
854.05% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.81
- EPS growth next 5 years12.53%
As of Nov 16, 2026